<!DOCTYPE HTML>

<!--[if IE ]>    <html lang="en" className="ie"> <![endif]-->

<!--[if !IE]><!--> <html lang="de"> <!--<![endif]-->



	<head>


		<meta charSet="utf-8">

		<title>History Timeline Rettungsanker</title>

		<meta name="description" content="jQuery Plugin for building timelines"/>

		<meta name="keywords" content=""/>

		<meta name="robots" content="index, follow"/>

		<meta name="viewport" content="width=device-width,initial-scale=1,minimum-scale=1,maximum-scale=1"/>



		<!-- CSS -->

		<link rel="stylesheet" href="./css/jquery.timeline.css" type="text/css" media="all">



	</head>



	<!-- BODY -->

	<body className="dark-demo fullwidth-demo">







			<!-- TIMELINE WRAPPER -->

			<div id="mytimeline" className="timeline-wrapper dark shadow" style="width: 1200px; height: 510px;">





				<!-- TIMELINE -->

				<div className="timeline" style="opacity: 1;">

						<!-- VIEWPORT - IMAGES -->

						<!-- NOTE: BETTER SPLIT IMAGES FOR SITE SPEED, BUT YOU CAN USE JUST ONE FULL IMAGE FOR ALL -->

						<!-- YOU CAN WRAP IMAGES INSIDE HREFS, FOR OPENING LIGHTBOX, LIKE THE SAMPLE BELOW -->



						<div className="viewport" style="height: 265px;"> 

							<div className="images ui-draggable ui-draggable-handle drag_icon" style="width: 8271px; left: 0px;">

               
 
                <img id="image_0000" src="/Jahr_2017.png" width="200" height="130" alt=""/>
                <img id="image_00001" src="/auf-der-reeperbahn.jpg" width=180" height="230" alt=""/>
                <img id="image_0001" src="/strassenschild_3.svg" width="210" height="180" alt=""/>
                <img id="image_0002" src="/LogoAlt.png" width="150" height="24" alt=""/>
                <img id="image_0003" src="/rettungsring.png" width="200" height="200" alt=""/>
                <img id="image_0004" src="/Impress03.jpg" width="240" height="200" alt=""/>
                <img id="image_0005" src="/Astraballons.png" width="100" height="160" alt=""/>
                <img id="image_0006" src="/Hero.png" width="300" height="180" alt=""/>
                <img id="image_0007" src="/Impress01.jpg" width="240" height="200" alt=""/>
                <img id="image_0008" src="/portrait-mick1.png" width="160" height="200" alt=""/>
                <img id="image_0009" src="/impress06.png" width="160" height="200" alt=""/>

               
             	</div>

						</div>



						<!-- SCROLLBAR (VIEW PLUGIN OPTIONS FOR STYLING) -->

            <div className="scrollbar" style="top: 244px; width: 2500px;">

							<div className="track" style="height: 21px; width: 2500px;">



								<!-- MARKS -->

								<!-- NOTE: MANUALLY POSITION (PERCENT %) EACH MARK WITH data-xpos ATTRIB -->

								<div className="marks">

                  <div data-xpos="4%" YYYYYYYYYYYYYYYYYYYYYYYYY original-title=""></div>

                  <div data-xpos="10%"YYYYYYYYYYYYYYYYYYYYYYYYY style="display: block; left: 10%; opacity: 1;" original-title=""></div>

                  <div data-xpos="20%"YYYYYYYYYYYYYYYYYYYYYYYYY style="display: block; left: 20%; opacity: 1;" original-title=""></div>

                  <div data-xpos="32%" data-label="1990’s" style="display: block; left: 32%; opacity: 1;" original-title=""></div>

                  <div data-xpos="47%" data-label="2000’s" style="display: block; left: 47%; opacity: 1;" original-title=""></div>

                  <div data-xpos="57%" data-label="2010’s" style="display: block; left: 57%; opacity: 1;" original-title=""></div>

								</div>



								<!-- DRAGGER -->

								<div className="dragger" ><!-- <img src="/scrollbar_dragger.png" alt="" /> --></div>

							</div>

						



						<!-- MILESTONES -->

						<div className="milestones" style="height: 215px;">

							<div className="content" style="width: 8213px; left: 0px;">



                <div className="column">

                  <div className="c300">

                    <div className="date decade">2017</div>
                      <div className="txt">

                      <strong>Die Idee</strong>

                      <br/>

                    </div>

                    <br/>

				    <div className="date">Januar 2017</div>

				    <div className="txt">

                    <strong>Eine erste Vision</strong><br/>

                    Michael Schreck und Volker Schneider planen in Hommage an eine Kiezkneipe auf St. Pauli die Neueröffnung eines Szenelokals in der Altstadt Freiburg.

                    </div>

										<span className="thumb"><a href="#extended_text1" data-rel="prettyPhoto" title=""><img src="/read_more.png" alt="" className="readmore" title="READ MORE" /></a></span>



										<div id="extended_text1" className="hidden">	<!-- SAMPLE OF HIDDEN DIV WITH EXTENDED CONTENT -->

											<p><strong>Homage an Kiezkneipe</strong><br/><br/>

											Bei einer gemeinsamen Reise nach Hamburg besuchen Volker Schneider Michael Schreck nach einem Fussballspiel in St. Pauli verschiedene Kiezkneipen auf der Reeperbahn. Nach einigen kühlen "Blonden" entsteht die Idee ein solche Kiezkneipe in der Freiburger Altstadt zu etablieren.</p>

										</div>

									</div>

								</div>

                      
                      
                      
                      
                      <!-- <div className="date">1967</div>

                    <div className="txt">

                      <strong>GC Company Established</strong> <br/>

                      Based just outside of Seoul, South Korea, the GC company is formed to achieve its mission- developing critical specialty pharmaceuticals, improving healthcare globally.</div>

                  </div>

                </div> -->



                <div className="column">

                  <div className="c300">

                    <div className="date decade">2017</div>

                    <div className="txt">

                      <strong>Der Standort</strong>

                      <br/>

                    </div>

                    <br/>

                    <div className="date">März 2017</div>

                    <div className="txt">

                      <strong>Alstadt Freibug</strong>

                      <br/>

                      Nach intensiver Suche kann in der Adelhauser-Strasse eine geeignete Lokalität für das Projekt "Kiezkneipe" gefunden werden. 

                    </div>

                  </div>

                </div>



								<div className="column">

									<div className="c300">

										<div className="date">April 2017</div>

										<div className="txt">

                      <strong>Ein Name und Logo sind gefunden</strong><br/>

                      Die neue Kiezkneipe wird Rettungsanker Freiburg als Namen erhalten.

                    </div>

										<span className="thumb"><a href="#extended_text1" data-rel="prettyPhoto" title=""><img src="/read_more.png" alt="" className="readmore" title="READ MORE" /></a></span>
1


										<div id="extended_text1" className="hidden">	<!-- SAMPLE OF HIDDEN DIV WITH EXTENDED CONTENT -->

											<p><strong>Production of GC’s Hemophilia Portfolio Begins</strong><br/><br/>

											GC began production of an antihemophilic factor (AHF) targeting Hemophilia A. In Hemophilia A (factor VIII deficiency) the body doesn’t make enough factor VIII, one of many substances needed to form a blood clot.  GC provided AHF to the South Korean Red Cross, free to the public through 1980 to improve public health throughout the country. GC- Devoted to Healthy Lives.</p>

										</div>

									</div>

								</div>



								<div className="column">

									<div className="c300">

							

										<div className="date">Mai 2017</div>

										<div className="txt">

                      <strong>Der Umbau</strong>

                      <br/>

                     Die Arbeiten der Inneneinrichtung und der Theke sind im vollen Gange. Unter der fachmännischen Leitung von Ralf Ritzel wird das Innenleben eines Schiffrumpfs eingebaut.

                    </div>

                    <span className="thumb"><a href="#extended_text2" data-rel="prettyPhoto" title=""><img src="/read_more.png" alt="" className="readmore" title="READ MORE" /></a></span>



                    <div id="extended_text2" className="hidden">  <!-- SAMPLE OF HIDDEN DIV WITH EXTENDED CONTENT -->

                      <p><strong>IV- Globulin Developed</strong><br/><br/>

                      There are over 350 Primary Immunodeficiencies recognized by the World Health Organization. GC began production of IVIG to treat lives affected by these conditions throughout South Korea and has since exported IVIG to over 50 countries.</p>

                    </div>

									</div>

								</div>



								<div className="column">

									<div className="c400">

                    <div className="date">September 2017</div>

                    <div className="txt">

                      <strong>Eröffnungsparty</strong>

                      <br/>

                      Endlich ist es soweit! In einer rauschenden und unvergesslichen Eröffnungsfeier wird der Rettungsanker vom Stapel gelassen. Zahlreiche geladene Gäste wohnen der Taufe der neuen Szenekneipe in der Freiburger Altstadt bei und feiern bisin den frühen morgen.    .

                    </div>

									</div>

								</div>



								<div className="column">

									<div className="c300">

										<div className="date">September 2018</div>

										<div className="txt">

                      <strong>Erster Geburtstag</strong><br/>

                      Der Rettungsanker feiert den ersten Geburtstag. Die "Kiezkneipe" hat sich bereits im ersten Jahres des Bestehens in der Freiburger Gastro-Szene voll etabliert.

                    </div>



									</div>

								</div>



								<div className="column">

									<div className="c300">

										<div className="date">September 2019</div>

                    <div className="txt">

                      <strong>Zweiter Geburtstag</strong><br/>

                      Der Rettungsanker feiert den zweiten Geburtstag.

                    </div>



									</div>

								</div>



                <div className="column">

                  <div className="c350">

                    <div className="date decade">2020</div>

                    <div className="txt">

                      <strong>NeuerCaptain</strong>

                    </div>

                    <br/>



                    <div className="date">1. Januar 2020</div>

                    <div className="txt">

                      <strong>Der Rettungsanker hat einen neuen Captain. Michael Schreck zeigt sich ab 1. Januar 2020 in alleiniger geschäftlicher Verantwortung für den Rettungsanker. Er wird den Rettungsanker in diesen stürmischen Zeiten der Pandemie sicher durch die wogende See führen. 

                    </div>

                    <span className="thumb"><a href="#extended_text3" data-rel="prettyPhoto" title=""><img src="/read_more.png" alt="" className="readmore" title="READ MORE" /></a></span>



                    <div id="extended_text3" className="hidden">  <!-- SAMPLE OF HIDDEN DIV WITH EXTENDED CONTENT -->

                      <p><strong>GC establishes a patient support foundation- the South Korean Hemophilia Foundation (KHF)</strong><br/><br/>

                      GC establishes the South Korea Hemophilia Foundation (KHF). The mission is to support the management and treatment of people with hemophilia, while assisting with the prevention, treatment, and rehabilitation.</p>

                    </div>

                  </div>

                </div>



                <div className="column">

                  <div className="c300">

                    <div className="date">

                      1993

                    </div>

                    <div className="txt">

                      <strong>Suduvax the world’s second varicella vaccine is approved in South Korea</strong><br/>

                      GC continues its focus and expansion in the vaccine marketplace and develops Suduvax-varicella vaccine in South Korea. The varicella vaccine protects against chickenpox, which is caused by the varicella-zoster virus. Suduvax is the first varicella vaccine produced in South Korea and the second vaccine produced in the world, further establishing GC as a leader in the Asian vaccine marketplace.

                    </div>

                  </div>

                </div>



                <!-- <div className="column">

                  <div className="c150">

                    <div className="date">1995</div>

                    <div className="txt">

                      <strong>GC penetrates into China establishing Anhui GC Bioproducts Ltd.</strong><br/>

                      Established GC in China, thereby paving the way for expansion into the local Chinese market for biological products.

                    </div>

                  </div>

                </div> -->



                <div className="column">

                    <div className="c250">

                    <div className="date decade">2000’s</div>
                        
                    <div className="txt"><strong>GC Expands in the US with Plasma Centers</strong></div>

                    <br/>

                    <div className="date">2009</div>

                    <div className="txt">

                      <strong>GC establishes new Plasma Centers in the US with the licensing of the GCAM-Plasma division</strong><br/>

                      GC sets up GC America (GCAM), to acquire, plasma collection centers.

                    </div>

                    <span className="thumb"><a href="#extended_text4" data-rel="prettyPhoto" title=""><img src="/read_more.png" alt="" className="readmore" title="READ MORE" /></a></span>



                    <div id="extended_text4" className="hidden">  <!-- SAMPLE OF HIDDEN DIV WITH EXTENDED CONTENT -->

                      <p><strong>GC establishes new Plasma Centers in the US with the licensing of the GCAM-Plasma division</strong>
                        <br/><br/>GC sets up GC America (GCAM), to acquire, plasma collection centers. The company has continued to expand its plasma collection facilities, ensuring a stable supply of plasma for its future pharmaceutical products in the US.</p>

                    </div>

                  </div>

                </div>



                <!-- <div className="column">

                  <div className="c175">

                    <div className="date">2009</div>

                    <div className="txt">

                      <strong>GC completes the buildout of the first flu vaccine manufacturing facility in S. Korea</strong><br/>

                      GC finished the construction of the Hwasun Plant, approved to manufacturer flu vaccines throughout S. Korea.

                    </div>

                    <span className="thumb"><a href="#extended_text5" data-rel="prettyPhoto" title=""><img src="/read_more.png" alt="" className="readmore" title="READ MORE" /></a></span>



                    <div id="extended_text5" className="hidden">  <!-- SAMPLE OF HIDDEN DIV WITH EXTENDED CONTENT -->

                <!--      <p><strong>GC completes the buildout of the first flu vaccine manufacturing facility in S. Korea</strong><br/><br/>GC finished the construction of the Hwasun Plant, approved to manufacturer flu vaccines throughout S. Korea.  The Hwasun plant became the 12th pharmaceutical facility in the world to succeed in developing a flu vaccine, which has gone on to popularize flu vaccinations in S. Korea playing a major role in preventing the spread of H1N1 in the country</p>

                    </div>

                  </div>

                </div> -->



                <div className="column">

                  <div className="c250">

                    <div className="date">2010</div>

                    <div className="txt">

                      <strong>Expansion Across the World and into the US</strong>

                    </div>

                    <br/>

                    <div className="date">2010</div>

                    <div className="txt">

                      <strong>Recombinant product GreenGene-F - approved for the treatment of Factor VIII disease in South Korea</strong>

                    </div>

                    <span className="thumb"><a href="#extended_text6" data-rel="prettyPhoto" title=""><img src="/read_more.png" alt="" className="readmore" title="READ MORE" /></a></span>



                    <div id="extended_text6" className="hidden">  <!-- SAMPLE OF HIDDEN DIV WITH EXTENDED CONTENT -->

                      <p><strong>Recombinant product GreenGene-F - approved for the treatment of Factor VIII disease in South Korea.</strong>
                        <br/><br/>
                        GC now produces a genetically encoded protein product to complement its portfolio of hemophilia and plasma-derived products in Asia.</p>

                    </div>

                  </div>

                </div>



                
                                
                <div className="column">

                  <div className="c250">

                    <div className="date">2012</div>

                    <div className="txt">

                      <strong>Hunterase gains approval in South Korea for the treatment of Hunter Syndrome</strong><br/>

                      Hunter Syndrome also called mucopolysaccharidosis II, or MPS II, is a rare genetic disorder mainly affecting boys. With Hunter Syndrome, the body cannot break down a specific sugar that is required to build bones, skin, tendons, and other tissue.

                    </div>

                    <span className="thumb"><a href="#extended_text5" data-rel="prettyPhoto" title=""><img src="/read_more.png" alt="" className="readmore" title="READ MORE" /></a></span>



                    <div id="extended_text5" className="hidden">  <!-- SAMPLE OF HIDDEN DIV WITH EXTENDED CONTENT -->

                <p><strong>Hunterase gains approval in South Korea for the treatment of Hunter Syndrome</strong><br/><br/>
                    Hunter Syndrome also called mucopolysaccharidosis II, or MPS II, a rare genetic disorder mainly affecting boys. With Hunter Syndrome, the body cannot break down a specific sugar that is required to build bones, skin, tendons, and other tissue. It results in a life expectancy of 10-20 years for those with a severe case and up to 60 years in milder cases. Hunterase is an enzyme replacement therapy that improves many of the signs and symptoms of Hunter Disease, as well as the overall wellbeing of MPS II patients.</p>

                    </div>

                  </div>

                </div>              
                                



                <div className="column">

                  <div className="c175">

                    <div className="date">2013</div>

                    <div className="txt">

                      <strong>GC completes the buildout of Research and Development (R&amp;D) Center in South Korea </strong><br/>

                      GC completes a state-of-the-art R&amp;D center. The new research facility is the cornerstone of GC’s future.

                    </div>

                  </div>

                </div>



                <div className="column">

                  <div className="c250">

                    <div className="date">2014</div>

                    <div className="txt">

                      <strong>GC brings Neulapeg into the Asian Market</strong><br/>

                      GC receives approval in South Korea for the injectable drug Neulapeg used in the treatment of neutropenia.

                    </div>

                    <br/>

                    <div className="date">2015</div>

                    <div className="txt">

                      <strong>GC completes the US- based study and publishes...</strong>

                    </div>

                    <span className="thumb"><a href="#extended_text7" data-rel="prettyPhoto" title=""><img src="/read_more.png" alt="" className="readmore" title="READ MORE" /></a></span>



                    <div id="extended_text7" className="hidden">  <!-- SAMPLE OF HIDDEN DIV WITH EXTENDED CONTENT -->

                        <p><strong>GC completes the US- based study and publishes “Efficacy, Safety, and Tolerability of IVIG-SN in Patients with Primary Immunodeficiency.”</strong><br/><br/>
                        An eleven investigator, multi-center IVIG trial is completed in the US. Immunologists, Mark Stein, Richard Wasserman et al. establish that IVIG-SN is safe and efficacious in the treatment of Primary Humoral Immune Deficiency.</p>

                    </div>

                  </div>

                </div>



                <div className="column">

                  <div className="c175">

                    <div className="date">2017</div>

                    <div className="txt">

                      <strong>GC establishes its first plant to manufacture plasma protein therapies in Canada.</strong><br/>GC establishes a strategic foothold by building its first plasma manufacturing facility in Montreal, Canada.

                    </div>

                   <span className="thumb"><a href="#extended_text8" data-rel="prettyPhoto" title=""><img src="/read_more.png" alt="" className="readmore" title="READ MORE" /></a></span>



                    <div id="extended_text8" className="hidden">  <!-- SAMPLE OF HIDDEN DIV WITH EXTENDED CONTENT -->

                      <p><strong>GC establishes its first plant to manufacture plasma protein therapies in Canada.</strong><br/><br/>GC establishes a strategic foothold by building its first plasma manufacturing facility in Montreal, Canada. GCBT is a new state-of-the-art facility, spanning 250,000 sq. ft. The facility will manufacturer IVIG and other plasma- based products for future distribution into Canada and the US.</p>

                    </div>

                  </div>

                </div>



                <div className="column">

                  <div className="c225">

                    <div className="date">2018</div>

                    <div className="txt">

                      <strong>Cuervo established in Seattle, WA. GC launches a new R&amp;D center in the US focusing on vaccines</strong><br/>

                      GC establishes a new research and development company focused on vaccine development in Seattle, WA. GC builds a strategic collaboration and partnership with global health organizations to form the new company.


                    </div>

                  </div>

                </div>



				<div className="column">

				    <div className="c250">

				    <div className="date">2018</div>



				    <div className="txt">

                      <strong>Artiva Company established in SanDiego, CA.  GC launches into research and development in natural killer cell therapy</strong><br/>

                      Executing on their vision as a global leader, GC opens a new research and development company based in San Diego, California. Artiva’s primary focus is in natural killer cell therapy research.

                    </div>

				    </div>

                </div>



                <div className="column">

                  <div className="c250">

                    <div className="date">2018</div>

                    <div className="txt">

                        <strong>GC establishes GC Biopharma USA, Inc., the IVIG sales, marketing and business operation division in the US. </strong><br/>
                        GC executes on its vision as a global leader in healthcare and establishes GC Biopharma USA, Inc. within the US.  Design and construction of its new corporate office is completed in Fort Lee, New Jersey. GC Biopharma USA, Inc. starts the commercialization process to launch IVIG.

                    </div>

                  </div>

                </div>



								<div className="column">

									<div className="c250">

                    <div className="date decade">2020 and Beyond</div>

										<div className="txt">

                      <strong>Global Innovation and Pipeline</strong>

                    </div>

									</div>

								</div>


							</div>	<!-- END CONTENT -->

						</div> <!-- END MILESTONES -->





				</div> <!-- END TIMELINE -->





			</div> <!-- END TIMELINE WRAPPER -->











		<!-- SCRIPTS -->

		<script type="text/javascript" src="./js/jquery-2.2.2.min.js"></script>

		<script type="text/javascript" src="./js/vendors.js"></script>

		<script type="text/javascript" src="./js/jquery.timeline.js"></script>



		<!-- LOAD PLUGIN ON DOCUMENT READY -->

		<script type="text/javascript">



			$(document).ready(function() {



				// START THE TIMELINE

				$("#mytimeline").timelineSlider({



					// SIZING OPTIONS

					timelineWidth: 2000,					// TIMELINE GLOBAL WIDTH, value in pixels OR 'auto' (WITH QUOTES) FOR FULLWIDTH

					timelineHeight: 550,				// TIMELINE GLOBAL HEIGHT, value in pixels

					upperAreaHeight: 265,				// UPPER AREA (IMAGES) HEIGHT, value in pixels

					lowerAreaHeight: 270,				// LOWER AREA (MILESTONES) HEIGHT, value in pixels

					draggerHeight: 22,					// DRAGGER (SCROLLBAR) HEIGHT, value in pixels



					// AUDIO OPTIONS

					audioPlayer: false,					// AUDIO PLAYER ACTIVE OR NOT, true OR false

					audioAutoPlay: false,				// MUSIC AUTOPLAY ON INIT, true OR false

					audioLoop: false,					// MUSIC RESTARTS AT THE END, true OR false



					// STYLING OPTIONS

					responsive: true,					// RESPONSIVE BEHAVIOUR, true OR false

					marksOnMobile: true,				// KEEP MARKS ON MOBILE (<768px), true OR false

					version: 'dark',					// LIGHT OR DARK THEME, 'light' OR 'dark'

					designStyle: 'default',				// DEFAULT OR FLAT DESIGN, 'default' OR 'flat'

					accentColor: '#FFC845',				// MAIN COLOR FOR TITLES AND EFFECTS, hexadecimal

					timelineBorderWidth: 5,				// BORDER FOR GLOBAL CONTAINER, in pixels

					timelineBorderColor: '#ffcc00',		// BORDER COLOR, hexadecimal

					shadow: true						// DISPLAY SHADOW BELOW THE TIMELINE, true OR false



				});



				/*

					TIP: THE ABOVE EXAMPLE SETTINGS OVERWRITE ALL THE DEFAULT ONES INSIDE THE PLUGIN.

					IF YOU ARE OK WITH MOST OF THE DEFAULT SETTINGS YOU CAN EVEN START THE TIMELINE WITH SIMPLE CALLS:



					// SIMPLE PLAIN PLUGIN CALL

					$("#mytimeline").timelineSlider();



					// SAMPLE CHANGING JUST THE WIDTH TO FULLWIDTH

					$("#mytimeline").timelineSlider({ timelineWidth: 'auto' });



					// SAMPLE CHANGING WIDTH TO FULLWIDTH & DISABLE AUDIO PLAYER

					$("#mytimeline").timelineSlider({ timelineWidth: 'auto', audioPlayer: false });

				*/







			});



		</script>



	</body>

</html>

